Crossmark

Oral administration of the 11β-hydroxysteroid-dehydrogenase type 1 inhibitor RO5093151 to patients with glaucoma: an adaptive, randomised, placebo-controlled clinical study

Crossref DOI link: https://doi.org/10.1136/bmjophth-2016-000063

Published Online: 2017-06-29

Published Print: 2017-06

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Schwab, Dietmar

Sturm, Carolina

Portron, Agnès

Fuerst-Recktenwald, Sabine

Hainzl, Dominik

Jordan, Paul

Stewart, William C

Tepedino, Michael E

DuBiner, Harvey
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct01493271 at ClinicalTrials.gov

Documents that mention this clinical trial

Oral administration of the 11β-hydroxysteroid-dehydrogenase type 1 inhibitor RO5093151 to patients with glaucoma: an adaptive, randomised, placebo-controlled clinical study
https://doi.org/10.1136/bmjophth-2016-000063
Funding

Funding for this research was provided by:

Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel

Document is current

Any future updates will be listed below